

Shaneice Mitchell

Casual - Non-Exempt, Pathology Sponsored Projects

Publications

PUBLICATIONS

- **Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease.** *European heart journal*
von Scheidt, M., Adkar, S. S., Krefting, J., Hoermann, G., Meggendorfer, M., Bauer, S., Mitchell, S., Pugach, I., Friess, C., Ma, A., Hao, K., Steigerwald, S., Wahle, et al
2025
- **The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/ β -catenin signaling.** *Experimental hematology & oncology*
Marr, A. R., Halpin, M., Corbin, D. L., Asemelash, Y., Sher, S., Gordon, B. K., Whipp, E. C., Mitchell, S., Harrington, B. K., Orwick, S., Benrashid, S., Goettl, V. M., Yildiz, et al
2024; 13 (1): 27
- **Multi- Omic Profiling of Macrophages Lacking Tet2 or Dnmt3a Reveals Mechanisms of Hyper-Inflammation in Clonal Hematopoiesis**
Rodrigues, K. B., Gopakumar, J., Weng, Z., Mitchell, S., Maurer, M., Nachun, D., Eulalio, T., Estrada, D., Mazumder, T., Ma, L., Montgomery, S., Jaiswal, S.
AMER SOC HEMATOLOGY.2023
- **Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis.** *Nature*
Weinstock, J. S., Gopakumar, J., Burugula, B. B., Uddin, M. M., Jahn, N., Belk, J. A., Bouzid, H., Daniel, B., Miao, Z., Ly, N., Mack, T. M., Luna, S. E., Prothro, et al
2023
- **The Multi-CDK Inhibitor Dinaciclib Shows Synergistic Activity with the BET Inhibitor PLX51107 and Reverses BET Resistance through Inhibition of Canonical Wnt Signaling in Acute Myeloid Leukemia (AML)**
Marr, A., Karmahapatra, S., Corbin, D., Asemelash, Y., Sher, S., Mitchell, S., Harrington, B. K., Orwick, S., Beaver, L., Wasmuth, R., Goettl, V., Mims, A. S., Larkin, et al
AMER SOC HEMATOLOGY.2022: 3075-3076
- **Black In Cardio: promoting diversity and representation in the cardiovascular field** *NATURE REVIEWS CARDIOLOGY*
Amartey, J., Okagbue, C., Saccoh, A., Buffonge, S., Francois, A., Tcheandjieu, C., Mitchell, S., Tyrrell, D. J., Mukaz, D.
2022
- **Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation.** *Journal of hematology & oncology*
Mitchell, S., Zhang, P., Cannon, M., Beaver, L., Lehman, A., Harrington, B., Sampath, D., Byrd, J. C., Lapalombella, R.
2021; 14 (1): 101
- **Targeting DNA damage repair functions of two histone deacetylases, HDAC8 and SIRT6, sensitizes acute myeloid leukemia to NAMPT inhibition.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Zhang, P., Brinton, L. T., Williams, K., Sher, S., Orwick, S., Lai, T., Mims, A. S., Coss, C. C., Kulp, S. K., Youssef, Y., Chan, W. K., Mitchell, S., Mustonen, et al
2021
- **Insights into clonal hematopoiesis and its relation to cancer risk.** *Current opinion in genetics & development*
Mitchell, S. R., Gopakumar, J., Jaiswal, S.
2021; 66: 63–69

- **BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor** *CANCER DISCOVERY*

Ozer, H., El-Gamal, D., Powell, B., Hing, Z. A., Blachly, J. S., Harrington, B., Mitchell, S., Grieselhuber, N. R., Williams, K., Lai, T., Alinari, L., Baiocchi, R. A., Brinton, et al
2018; 8 (4): 458-477

- **Next-generation XPO1 inhibitor shows improved efficacy and *in vivo* tolerability in hematological malignancies** *LEUKEMIA*

Hing, Z. A., Fung, H. J., Ranganathan, P., Mitchell, S., El-Gamal, D., Woyach, J. A., Williams, K., Goettl, V. M., Smith, J., Yu, X., Meng, X., Sun, Q., Cagatay, et al
2016; 30 (12): 2364-2372